VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Sunday, January 11, 2026

Wide Moat StocksExpansion-Stage Stocks Home My Collections

Stock Comparison

InterContinental Hotels Group PLC vs Novo Nordisk A/S

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

InterContinental Hotels Group PLC

IHG · London Stock Exchange

Market cap (USD)$18.8B
Gross margin (TTM)—
Operating margin (TTM)—
Net margin (TTM)—
SectorConsumer
Industry—
CountryGB
Data as of2026-01-10
Moat score
57/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into InterContinental Hotels Group PLC's moat claims, evidence, and risks.

View IHG analysis

Novo Nordisk A/S

NOVOB · Nasdaq Copenhagen

Market cap (USD)$1.7T
Gross margin (TTM)82.1%
Operating margin (TTM)42%
Net margin (TTM)32.9%
SectorHealthcare
IndustryBiotechnology
CountryDK
Data as of2025-12-28
Moat score
85/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Novo Nordisk A/S's moat claims, evidence, and risks.

View NOVOB analysis

Comparison highlights

  • Moat score gap: Novo Nordisk A/S leads (85 / 100 vs 57 / 100 for InterContinental Hotels Group PLC).
  • Segment focus: InterContinental Hotels Group PLC has 5 segments (36% in Fee business (franchise, management and ancillary fees)); Novo Nordisk A/S has 3 segments (71.1% in Diabetes care).
  • Moat breadth: InterContinental Hotels Group PLC has 8 moat types across 3 domains; Novo Nordisk A/S has 5 across 3.

Primary market context

InterContinental Hotels Group PLC

Fee business (franchise, management and ancillary fees)

Market

Branded hotel franchising and management services

Geography

Global

Customer

Hotel owners and developers

Role

Franchisor and hotel manager (asset-light brand platform)

Revenue share

36%

Novo Nordisk A/S

Diabetes care

Market

Diabetes pharmaceuticals (GLP-1 for type 2 diabetes, insulin, and related therapies)

Geography

Global

Customer

Payers/providers and patients (via wholesalers/pharmacies/hospitals)

Role

Originator pharma (R&D, regulatory, manufacturing, commercialization)

Revenue share

71.1%

Side-by-side metrics

InterContinental Hotels Group PLC
Novo Nordisk A/S
Ticker / Exchange
IHG - London Stock Exchange
NOVOB - Nasdaq Copenhagen
Market cap (USD)
$18.8B
$1.7T
Gross margin (TTM)
n/a
82.1%
Operating margin (TTM)
n/a
42%
Net margin (TTM)
n/a
32.9%
Sector
Consumer
Healthcare
Industry
n/a
Biotechnology
HQ country
GB
DK
Primary segment
Fee business (franchise, management and ancillary fees)
Diabetes care
Market structure
Oligopoly
Oligopoly
Market share
n/a
33.7% (reported)
HHI estimate
n/a
n/a
Pricing power
Moderate
Moderate
Moat score
57 / 100
85 / 100
Moat domains
Demand, Supply, Network
Legal, Supply, Demand
Last update
2026-01-10
2025-12-28

Moat coverage

Shared moat types

Brand Trust

InterContinental Hotels Group PLC strengths

Scale Economies Unit CostLong Term ContractsTwo Sided NetworkDistribution ControlPass-through reimbursement revenueAsset-heavy hotel operations (limited moat)Immaterial ancillary activity

Novo Nordisk A/S strengths

IP Choke PointRegulated Standards PipeCapacity MoatLearning Curve Yield

Segment mix

InterContinental Hotels Group PLC segments

Full profile >

Fee business (franchise, management and ancillary fees)

Oligopoly

36%

System Fund (marketing, reservations and loyalty assessments)

Monopoly

32.7%

Reimbursable revenues (managed hotel staff reimbursements)

Competitive

20.3%

Owned, leased and managed lease hotels

Competitive

10.5%

Insurance activities (ancillary)

Competitive

0.5%

Novo Nordisk A/S segments

Full profile >

Diabetes care

Oligopoly

71.1%

Obesity care

Duopoly

22.4%

Rare disease

Oligopoly

6.4%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Looking for expansion-stage stocks?

Proven models entering the expansion stage with unit economics that work.

View expansion-stage stocks

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.